This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein:

(- - -) represents a double bond;

X_1 is -O-;

n is an integer from 1 to 6;

the aryl rings are each optionally and independently substituted;

the alkylene spacer molecule between the piperidine and the $-CO_2R$ group is substituted with a cyclic alkyl or a heterocycle, wherein one or more of the carbons of the spacer molecule is contained in the cyclic alkyl or the heterocycle; and

R is -H, 2-propyl, 2-butyl, 2-pentyl, cyclopentyl, cyclohexyl, 3-tetrahydrofuryl, 3-pentyl, 1,3-dimethoxy-2-propyl, 4-tetrahydropyranyl, 2,4-dimethyl-3-pentyl, 1-methoxy-2-propyl, 1-3-diethoxy-2-propyl, or 2,2'dimethyl-l-propyl.

2. (Original) The compound of claim 1, wherein R is -H.

3. (Previously Presented) The compound of claim 1, wherein:

the aryl rings are each optionally and independently substituted with one or more groups selected from halogen, dimethylaminocarbonyl, fluoroalkyl, hydroxy, C_{1-6}

alkyl, C_{1-6} alkoxy, carboxylic acid, methylhydroxy, methylcarbonyl, cyano, aminomethyl, (aminoalkyl), ethoxycarbonylmethoxy, cyanomethyloxy, (acetoxyethyl)oxy, (hydroxyoxyethyl)oxy, morphilinoethyloxy, (tetrazol-5-yl)methyloxy, carboxymethyloxy, dimethylaminocarbonylmethyloxy, morphilinocarbonylmethyloxy, (1-ethoxycarbonyl-1-methylethyl)oxy, (1-carboxy-1-methylethyl)oxy, (2-methoxyethyl)oxy, (1-dimethylaminocarbonyl-1-methylethyl)oxy, (1-ethoxycarbonyl)cyclobutoxy, (1-carboxy)cyclobutoxy, (1,1-dimethyl-2-hydroxyethyl)oxy, (2,2-dimethyl-2-hydroxyethyl)oxy, acyloxy, cycloalkyl, arylalkyl, alkoxycarbonyl, and substituted or unsubstituted amines.

4. (Currently Amended) The compound of claim 1, wherein:

the aryl rings are optionally and independently substituted with one or more substituents selected from hydrogen, halogen, alkyl, fluoroalkyl, hydroxy, alkoxy, $-(O)_u-(CH_2)_t-C(O)OR_4$, $-(O)_u-(CH_2)_t-OC(O)R_4$, $-(O)_u-(CH_2)_t-C(O)-NR_5R_6$ and $-(O)_u-(CH_2)_t-NHC(O)O-R_4$;

wherein:

t is an integer from 0 to 3;

u is 0 or 1;

$-(CH_2)_t-$ is substituted or unsubstituted; and

R_4, R_5, and R_6 are independently hydrogen, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group or a non-aromatic heterocyclic group, or R_5 and R_6, taken together with the nitrogen atom to which they are bonded, are a non-aromatic heterocyclic ring.

5. (Currently Amended) The compound of claim 1, wherein:

the aryl rings are optionally and independently substituted with one or more of halogen, -OH, $-CO_2H$, alkylimine, alkylsulfonyl, carboxamido, carboxylic alkyl esters, -CH=NH, $-NO_2$, azido, cyano, fluoroalkyl, $-CONR_8R_9$, $-NR_8R_9$, $-OS(O)_2NR_8R_9$, $-S(O)_2NR_8R_9$, sulfonic acid, sulfonamide, guanidino, $-(O)_u-(CH_2)_t-C(O)OR_4$, $-(O)_u-(CH_2)_t-OC(O)R_4$, $-(O)_u-(CH_2)_t-C(O)-NR_5R_6$, $-(O)_u-(CH_2)_t-NHC(O)O-R_4$, -Q-H, -Q-(aliphatic group), -Q-(substituted aliphatic group), -Q-(aryl), -Q-(aromatic group), -Q-(substituted aromatic group), $-Q-(CH_2)_p-$

(substituted or unsubstituted aromatic group), -Q-(non-aromatic heterocyclic group) or –Q-$(CH_2)_p$-(non-aromatic heterocyclic group);

wherein:

p is an integer from 1 to 5;

u is 0 or 1;

t is an integer from 0 to 3;

Q is –O-, -S-, -S(O)-, -$S(O)_2$-, -$OS(O)_2$-, -C(O)-, -OC(O)-, -C(O)O, -C(O)C(O)-O-, -O-C(O)C(O)-, -C(O)NH-, -NHC(O)-, -OC(O)NH-, -NHC(O)O-, NH-C(O)-NH-, -$S(O)_2$ NH-, -$NHS(O)_2$-, -$N(R_7)$-, -$C(NR_7)NHNH$-, -$NHNHC(NR_7)$-, -$NR_8C(O)$- or –NR_8 $S(O)_2$-;

R_4, R_5, and R_6 are independently – H, an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a non-aromatic heterocyclic group, -NHC(O)-O-(aliphatic group), -NHC(O)-O- (aromatic group) or –NHC(O)-O-(non-aromatic heterocyclic group), or R_5 and R_6, taken together with the nitrogen atom to which they are bonded, are a non-aromatic heterocyclic ring;

R_7 is –H, an aliphatic group, a benzyl group, an aryl group or a non-aromatic heterocyclic group; and

R_8 and R_9 are independently –H, hydroxy, an aliphatic group, a substituted aliphatic group, a benzyl group, an aryl group or a non-aromatic heterocyclic group.

6. (Previously Presented) The compound of claim 2, wherein the compound is represented by the following formula:



wherein:

n is 1, 2, or 3;

R_1 = -H, -OH, $-CH_2OH$, or $-CH_2CH_2OH$;

R_2 = -H, $-CH_3$, $-CF_3$, -Cl, or -Br;

X_1 is -O-; and

the alkylene spacer molecule is: substituted with a cyclic alkyl or a heterocycle, wherein one or more of the carbons of the spacer molecule is contained in the cyclic alkyl or the heterocycle.

7.-12. (Canceled).

13. (Previously Presented) The compound of claim 1, wherein the alkylene spacer is substituted with a cyclic alkyl, wherein one or more of the carbons of the spacer molecule is contained in the cyclic alkyl.

14. (Previously Presented) The compound of claim 13, wherein the cyclic alkyl is a cyclopropyl group.

15. (Previously Presented) The compound of claim 14, wherein one of the carbons of the spacer molecule is contained in the cyclic alkyl.

16. (Previously Presented) The compound of claim 6, wherein the compound is selected from the group of compounds consisting of:







and



17. (Previously Presented) The compound of claim 1, wherein the compound is represented by the following formula:



wherein:

n is 1, 2, or 3;

the alkylene spacer is substituted with a cyclic alkyl or a heterocycle, wherein one or more of the carbons of the spacer molecule is contained in the cyclic alkyl or the heterocycle;

R_1 and R_2 are independently selected from one or more groups selected from halogen, dimethylaminocarbonyl, fluoroalkyl, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, carboxylic acid, methylhydroxy, methylcarbonyl, cyano, aminomethyl, (aminoalkyl), ethoxycarbonylmethoxy, cyanomethyloxy, (acetoxyethyl)oxy, (hydroxyoxyethyl)oxy, morphilinoethyloxy, (tetrazol-5-yl) methyloxy, carboxymethyloxy, dimethylaminocarbonylmethyloxy, morphilinocarbonylmethyloxy, (1-ethoxycarbonyl-1-methylethyl)oxy, (1-carboxy-1methylethyl)oxy, (2-methoxyethyl)oxy, (1-dimethylaminocarbonyl-1-methylethyl)oxy, (1-ethoxycarbonyl)cyclobutoxy, (1-carboxy)cyclobutoxy, (1,1-dimethyl-2-hydroxyethyl)oxy, (2,2-dimethyl-2-hydroxyethyl)oxy, acyloxy, cycloalkyl, arylalkyl, alkoxycarbonyl, and substituted or unsubstituted amines; and

X_1 is -O-.

18. (Previously Presented) The compound of claim 1, wherein the alkylene spacer molecule is substituted with a cyclic alkyl or a heterocycle selected from cyclopropyl, tetrahydropyranyl, tetrahydrofuranyl, and cyclohexyl.

19. (Previously Presented) A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein:

(- - -) represents double bond;

X_1 is -O-;

n is an integer from 1 to 6;

the aryl rings are each optionally and independently substituted;

the alkylene spacer molecule between the piperidine and the $-CO_2R$ group is substituted with cyclopropyl, wherein one or more of the carbons of the spacer molecule is contained in the cyclopropyl ring; and

R is -H, 2-propyl, 2-butyl, 2-pentyl, cyclopentyl, cyclohexyl, 3-tetrahydrofuryl, 3-pentyl, 1,3-dimethoxy-2-propyl, 4-tetrahydropyranyl, 2,4-dimethyl-3-pentyl, 1-methoxy-2-propyl, 1-3-diethoxy-2-propyl, or 2,2'dimethyl-l-propyl.

20. (Previously Presented) A compound represented by the following structural formula:



wherein:

n is 1, 2, or 3;

the alkylene spacer is substituted with cyclopropyl, wherein one of the carbons of the spacer molecule is contained in the cyclopropyl ring;

R_1 and R_2 are independently selected from one or more groups selected from halogen, dimethylaminocarbonyl, fluoroalkyl, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, carboxylic acid, methylhydroxy, methylcarbonyl, cyano, aminomethyl, (aminoalkyl), ethoxycarbonylmethoxy, cyanomethyloxy, (acetoxyethyl)oxy, (hydroxyoxyethyl)oxy, morphilinoethyloxy, (tetrazol-5-yl) methyloxy, carboxymethyloxy, dimethylaminocarbonylmethyloxy, morphilinocarbonylmethyloxy, (1-ethoxycarbonyl-1-methylethyl)oxy, (1-carboxy-1methylethyl)oxy, (2-methoxyethyl)oxy, (1-dimethylaminocarbonyl-1-methylethyl)oxy, (1-ethoxycarbonyl)cyclobutoxy, (1-carboxy)cyclobutoxy, (1,1-dimethyl-2-hydroxyethyl)oxy, (2,2-dimethyl-2-hydroxyethyl)oxy, acyloxy, cycloalkyl, arylalkyl, alkoxycarbonyl, and substituted or unsubstituted amines; and

X_1 is -O-.

Amendments to the specification are as follows:

Please replace Scheme 14 and Scheme 15 in their entirety (at pages 90 and 91 of the as-filed application) with the following amended Scheme 14 and Scheme 15:

Scheme 14



Scheme 15


NaO
COOH
TFAA, BF_3
DCM
COOEt
$TiCl_4$-2THF
Zn, THF
NaOH
EtOH, H_2O
EtOOC
(i)
COOMe
K_2CO_3
(ii) Hydrolysis
OH
HO